LUMYKRAS

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Israel, Italy, Lithuania, Poland, Romania, UK.

Active ingredients

The drug LUMYKRAS contains one active pharmaceutical ingredient (API):

1	Sotorasib UNII 2B2VM6UC8G - SOTORASIB
	Sotorasib is a selective KRAS G12C (Kirsten rat sarcoma viral oncogene homolog) inhibitor, which covalently and irreversibly binds to the unique cysteine of KRAS G12C. Inactivation of KRAS G12C by sotorasib blocks tumour cell signalling and survival, inhibits cell growth, and promotes apoptosis selectively in tumours harbouring KRAS G12C, an oncogenic driver of tumourigenesis.
	Read more about Sotorasib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LUMYKRAS Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XX73		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX73

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1873212, 1873223, 1873234
FI	Lääkealan turvallisuus- ja kehittämiskeskus	421007
FR	Base de données publique des médicaments	63966283
IL	מִשְׂרַד הַבְּרִיאוּת	9221
IT	Agenzia del Farmaco	049858018, 049858020, 049858032
LT	Valstybinė vaistų kontrolės tarnyba	1093934, 1093935, 1093936
PL	Rejestru Produktów Leczniczych	100462468
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69079001, W69079002, W69079003